We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Silica Nanoparticles Adapted to Deliver Water-Insoluble Cancer Drugs

By Biotechdaily staff writers
Posted on 21 Jun 2007
Cancer researchers have found a way to administer hydrophobic chemotherapeutic drugs that does not require dissolving the medication in toxic solvents.

Investigators at the Jonsson Cancer Center (Los Angeles, CA, USA) used the pores of fluorescent mesoporous (i.e., containing pores with diameters between 2 and 50 nm) silica nanoparticles to sequester the hydrophobic anticancer drug camptothecin (CPT). More...
This drug and its derivatives are considered to be among the most effective of the currently available anticancer drugs. Although studies have demonstrated their effectiveness against a number of different types of cancer cells in vitro, clinical application of CPT in humans has only been carried out with derivatives that have improved water solubility.

Results published in the June 2007 issue of the journal Small showed that silica nanoparticles containing CPT were taken up by cancer cells, which then began to die. "In order to be used on humans, current cancer therapies such as CPT or Taxol, which are poorly water-soluble, must be mixed with organic solvents in order to be delivered into the body,” said senior author Dr. Fuyuhiko Tamanoi, professor of microbiology, immunology, and molecular genetics at the Jonsson Cancer Center. "These elements produce toxic side effects and in fact decrease the potency of the cancer therapy. Silica nanomaterials show promise for delivering camptothecin and other water-insoluble drugs. We have successfully loaded hydrophobic anticancer drugs into mesoporous nanoparticles and delivered them into human cancer cells to induce cell death.”


Related Links:
Jonsson Cancer Center

Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: Associate Professor Arutha Kulasinghe and non-small cell lung cancer cell (Photo courtesy of The University of Queensland)

Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer

Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.